早期貧血管理

Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses. （開啟新視窗）

Ball AM, Winstead PS.

來源‎: Pharmacotherapy 2008;28(11):1383-90.

Recombinant human erythropoietin in severe anaemia: issues of dosing and duration. （開啟新視窗）

Charles A, Purtill M, Napolitano LM.

來源‎: Anaesth Intensive Care 2006;34(6):793-6.

Thalidomide for recurrent bleeding due to small-intestinal angiodysplasia. （開啟新視窗）

Chen H, Wu S, Tang M, Zhao R, Zhang Q, Dai Z, Gao Y, Yang S, Li Z, Du Y, Yang A, Zhong L, Lu L, Xu L, Shen X, Liu S, Zhong J, Li X, Lu H, Xiong H, Shen Y, Chen H, Gong S, Xue H, Ge Z

來源‎: N Engl J Med. 2023 2;389(18):1649-59.

Bloodless management of the anemic patient in the emergency department. （開啟新視窗）

Johnson-Arbor K, Verstraete R

來源‎: Ann Emerg Med 2022;79(1):48-57.

Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. （開啟新視窗）

Napolitano LM, Fabian TC, Kelly KM, Bailey JA, Block EF, Langholff W, Enny C, Corwin HL.

來源‎: J Trauma 2008;65(2):285-97.

Erythropoiesis in multiply injured patients. （開啟新視窗）

Robinson Y, Hostmann A, Matenov A, Ertel W, Oberholzer A.

來源‎: J Trauma 2006;61(5):1285-91.

Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: a prospective study. （開啟新視窗）

Talving P, Lustenberger T, Inaba K, Lam L, Mohseni S, Chan L, Demetriades D.

來源‎: Arch Surg 2012;147(3):251-5.

Zeugen Jehovas und Schwerverletzung mit drohender Hämorrhagie. Wie komplex ist die Behandlung? [Jehovah's Witnesses and severe injury with impending hemorrhaging: how complex is the treatment?] [German, English abstract] （開啟新視窗）

Zeckey C, Vanin N, Neitzke G, Mommsen P, Bachmann S, Frink M, Wilhelmi M, Krettek C, Hildebrand F.

來源‎: Chirurg 2011;82(6):531-5.

給專業醫療人員的資訊